

NONGENETIC CAUSES OF HYPERTYROSINEMIA THAT MUST BE CONSIDERED WHEN INTERPRETING A FINDING OF ELEVATED URINARY TYROSINE

CAUSAS NO GENÉTICAS DE HIPERTIROSINEMIA QUE DEBEN CONSIDERARSE AL INTERPRETAR UN HALLAZGO DE TIROSINA ELEVADA EN ORINA

Manuel André Virú-Loza  ^{1,2,a,b}

Mr Editor:

In several countries newborns are screened for tyrosinemia type 1 using tyrosine as a primary marker⁽¹⁾. In some situations elevated tyrosine levels in blood are discovered due to elevated tyrosine in a metabolic urine screening⁽²⁾. In Peru, some pediatric patients suspected of having a genetic condition (inborn error of metabolism) undergo a metabolic urine screening that includes - among other things - qualitative detection of tyrosine. However, when there are elevated levels of tyrosine in urine this does not always mean that the patient has a genetic condition^(2,3). Most often hypertyrosinemia has a non-genetic origin⁽²⁾. Therefore, it is important to review the non-genetic causes of hypertyrosinemia and thus avoid potential misinterpretations of this finding.

The genetic entities associated with increased levels of tyrosine are those that generate an enzymatic deficiency in the degradation of tyrosine, within which tyrosinemias type I, II or III are included^(2,3). However, elevated tyrosine levels in the blood usually have a nongenetic cause⁽²⁾. The most common non-genetic cause of increased tyrosine levels in the blood is transient tyrosinemia of the newborn⁽²⁾. This is due to immaturity of enzymes involved in tyrosine degradation^(2,3). – such as 4-hydroxyphenylpyruvate dioxygenase⁽⁴⁾. – such as 4-hydroxyphenylpyruvate dioxygenase⁽⁴⁾.

It should be noted that two full-term infants have been reported to have received high-protein diets (3 to 4 times more than recommended), so the tyrosine concentration was > 10 times normal⁽⁵⁾. Plasma tyrosine quickly returned to normal after switching to an appropriate formula⁽⁵⁾. Therefore, even in full-term infants, a diet high in protein is a risk factor for transient tyrosinemia in the newborn⁽⁵⁾. In fact, some authors point out that in general, hypertyrosinemia could be caused by a diet with sufficiently high levels of proteins⁽³⁾ and by vitamin C deficiency^(2,4).

¹ Departamento de Pediatría, Hospital Nacional Edgardo Rebagliati Martins. Lima, Perú.

² Facultad de Medicina Humana, Universidad Ricardo Palma. Lima, Perú.

^a Pediatric physician specializing in Endocrinology.

^b Master of Science in Epidemiological Research.

Cite as: Virú-Loza MA. Nongenetic causes of hypertyrosinemia that must be considered when interpreting a finding of elevated urinary tyrosine. Rev Fac Med Hum. 2023;23(1):143-144. [doi:10.25176/RFMH.v23i1.3620](https://doi.org/10.25176/RFMH.v23i1.3620)

Journal home page: <http://revistas.urp.edu.pe/index.php/RFMH>

Article published by the Magazine of the Faculty of Human Medicine of the Ricardo Palma University. It is an open access article, distributed under the terms of the Creative Commons License: Creative Commons Attribution 4.0 International, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>), that allows non-commercial use, distribution and reproduction in any medium, provided that the original work is duly cited. For commercial use, please contact revista.medicina@urp.pe

Transient tyrosinemia of the newborn resolves spontaneously and no significant negative effects are generally observed, even more so if hypertyrosinemia has been maintained only for a short period^(4,5). However, mild developmental delay⁽⁴⁾ and learning disabilities have been reported after 9 years of follow-up, especially in those with very high tyrosine levels (>1100 $\mu\text{mol/L}$)⁽⁵⁾, as increased levels of tyrosine in the blood apparently do not cause disease if they are < 500 μM ⁽²⁾.

Although the resolution is spontaneous, it should be noted that there is a rapid response to pharmacological doses of vitamin C⁽²⁾. Liver dysfunction or failure of any cause can lead to elevated tyrosine in the blood and

Authorship contributions: The author made the conception, search for information, drafting and approval of the final version of the article.

Financing: Self-financed.

Correspondence: Manuel André Virú-Loza.

Address: Jr. Piedra Bigua 2241-A, San Juan de Lurigancho.

Telephone number: (01) 2654901

E-mail: m.andre.viru@gmail.com

REFERENCES

1. La Marca G, Malvagía S, Pasquini E, Cavicchi C, Morrone A, Ciani F, et al. Newborn Screening for Tyrosinemia Type I: Further Evidence that Succinylacetone Determination on Blood Spot Is Essential. *JIMD Rep.* 2011;1:107-9. https://doi.org/10.1007/8904_2011_24
2. Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. *Semin Liver Dis.* 2001;21(4):563-71. <https://doi.org/10.1055/s-2001-19035>
3. Sniderman King L, Trahms C, Scott C. Tyrosinemia Type I [Internet]. 2006 Jul 24 [Updated 2017 May 25]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews*[®] [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1515/>
4. Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: A review. *Pediatr Dev Pathol.* 2001;4(3):212-21. <https://doi.org/10.1007/s100240010146>
5. Techakittiroj C, Cunningham A, Hooper PF, Andersson HC, Thoene J. High protein diet mimics hypertyrosinemia in newborn infants. *J Pediatr.* 2005;146(2):281-2. <https://doi.org/10.1016/j.jpeds.2004.10.013>

increased excretion of tyrosine metabolites in urine⁽²⁻⁴⁾. Tyrosine levels in these cases are usually < 500 μM ⁽²⁾. Because the latter is also observed in hereditary tyrosinemia type 1 (fumaryl acetoacetate hydrolase deficiency), in cases of liver damage the measurement of plasma alpha-fetoprotein and urine succinylacetone is important to define the cause⁽²⁾.

Hypertyrosinemia may also occur in other situations, such as a blood sample without previous fasting (postprandial sample)^(2,4), hyperthyroidism^(2,4) and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione) therapy⁽²⁾. Therefore, there are non-genetic causes of hypertyrosinemia that must be considered to avoid false positives.

Conflicts of interest: Author declares no conflicts of interest.

Received: february 30, 2021

Approved: december 10, 2022